Adage Capital Partners Gp, L.L.C. Ultragenyx Pharmaceutical Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $59.7 Billion
- Q3 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 430,000 shares of RARE stock, worth $14.2 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
430,000
Previous 1,529,474
71.89%
Holding current value
$14.2 Million
Previous $55.6 Million
76.74%
% of portfolio
0.02%
Previous 0.1%
Shares
25 transactions
Others Institutions Holding RARE
# of Institutions
351Shares Held
88.3MCall Options Held
2.23MPut Options Held
1.06M-
Vanguard Group Inc Valley Forge, PA10.1MShares$335 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$185 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY4.01MShares$133 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA3.77MShares$125 Million0.33% of portfolio
-
State Street Corp Boston, MA3.69MShares$122 Million0.0% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $2.32B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...